{"prompt":"*title*: 0.1 g\/kg Octagam 10% Every 2 Weeks *description*: Participants received 0.1 g\/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" octagam %%%"}
{"prompt":"*title*: 0.2 g\/kg Octagam 10% Every 4 Weeks *description*: Participants received 0.2 g\/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" octagam %%%"}
{"prompt":"*title*: 0.25 g\/kg Octagam 10% Every 2 Weeks *description*: Participants received 0.25 g\/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" octagam %%%"}
{"prompt":"*title*: 0.4 g\/kg Octagam 10% Every 2 Weeks *description*: Participants received of 0.4 g\/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" octagam %%%"}
{"prompt":"*title*: 0.5 g\/kg Octagam 10% Every 4 Weeks *description*: Participants received 0.5 g\/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" octagam %%%"}
{"prompt":"*title*: 0.8 g\/kg Octagam 10% Every 4 Weeks *description*: Participants received of 0.8 g\/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" octagam %%%"}
{"prompt":"*title*: 1% OPC-12759 Ophthalmic Suspension *description*: 1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.\n\n$$$\n\n","completion":" opc-12759 %%%"}
{"prompt":"*title*: 1. Pioglitazone *description*: Pioglitazone: Pioglitazone tablets; 30 mg\/day for 2 weeks; then increased to 45 mg\/day until week 12 (approximately 3 months)\n\n$$$\n\n","completion":" pioglitazone %%%"}
{"prompt":"*title*: 10 mg IR in Study 326 *description*: Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.\n\n$$$\n\n","completion":" donepezil ir %%%"}
{"prompt":"*title*: 2% OPC-12759 Ophthalmic Suspension *description*: 2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.\n\n$$$\n\n","completion":" opc-12759 %%%"}
{"prompt":"*title*: 2. Placebo *description*: Placebo: Matching placebo (inert tablet)\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: 23 mg SR in Study 326 *description*: Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.\n\n$$$\n\n","completion":" donepezil sr %%%"}
{"prompt":"*title*: ACC-001 10 Micrograms + QS-21 *description*: A cohort of participants who received IM injection of active vaccine ACC-001 (10 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12\n\n$$$\n\n","completion":" acc-001 ### qs-21 %%%"}
{"prompt":"*title*: ACC-001 3 Micrograms + QS-21 *description*: A cohort of participants who received intramuscular (IM) injection of active vaccine ACC-001 (3 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 3, 6, 9 and 12\n\n$$$\n\n","completion":" acc-001 ### qs-21 %%%"}
{"prompt":"*title*: ACC-001 30 Micrograms + QS-21 *description*: A cohort of participants who received IM injection of active vaccine ACC-001 (30 micrograms) + adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12\n\n$$$\n\n","completion":" acc-001 ### qs-21 %%%"}
{"prompt":"*title*: Albiglutide *description*: Albiglutide was administered once weekly as subcutaneous injection in the abdomen, thigh or upper arm region. Participants were administered albiglutide at a dose of 30 milligrams (mg) or 50 mg once weekly in addition to the standard of care therapy for diabetes and cardiovascular health.\n\n$$$\n\n","completion":" albiglutide %%%"}
{"prompt":"*title*: Aliskiren\/HCTZ *description*: Aliskiren \/ HCTZ 150\/12.5 mg for 1 week followed by 300\/25 mg for 7 weeks\n\n$$$\n\n","completion":" aliskiren ### hctz %%%"}
{"prompt":"*title*: Aminophylline 250 mg *description*: Aminophylline 250 mg IV drip administration\n\n$$$\n\n","completion":" aminophylline %%%"}
{"prompt":"*title*: Amlodipine *description*: Amlodipine 5 mg for 1 week followed by 10 mg for 7 weeks\n\n$$$\n\n","completion":" amlodipine %%%"}
{"prompt":"*title*: Arm 1: (Docetaxel, Carboplatin, Pegylated G-CSF) *description*: Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles\nPegylated G-CSF on day 2 every 21 days for maximum of 6 cycles\n\n$$$\n\n","completion":" carboplatin ### docetaxel ### pegylated g-csf %%%"}
{"prompt":"*title*: Arm 1: Pioglitazone *description*: Current or former smokers receive 6 months of treatment with pioglitazone\n\nfluorescence bronchoscopy: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.\n\nquantitative high resolution CT scan: High resolution CT scan of the chest\n\nPIOGLITAZONE VS. PLACEBO 30 mg: Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-\n\nactivated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials.\n\n$$$\n\n","completion":" pioglitazone %%%"}
{"prompt":"*title*: Arm 2: Placebo *description*: Current or former smokers receive 6 months of treatment with placebo\n\nfluorescence bronchoscopy: examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.\n\nquantitative high resolution CT scan: High resolution CT scan of the chest\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Arm I: Docetaxel *description*: Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.\n\ndocetaxel: Given IV\n\nvandetanib: Given orally\n\n$$$\n\n","completion":" docetaxel ### vandetanib %%%"}
{"prompt":"*title*: Arm II: Docetaxel + Vandetanib *description*: Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\ndocetaxel: Given IV\n\nvandetanib: Given orally\n\n$$$\n\n","completion":" vandetanib ### docetaxel %%%"}
{"prompt":"*title*: BRCA-positive Ovarian Cancer: ABT-888 & Cyclophosphamide *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" abt-888 ### cyclophosphamide %%%"}
{"prompt":"*title*: BRCA-positive Ovarian Cancer: Crossover *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" abt-888 ### cyclophosphamide %%%"}
{"prompt":"*title*: BRCA-positive Ovarian Cancer: Cyclophosphamide Alone *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days.\n\n$$$\n\n","completion":" cyclophosphamide %%%"}
{"prompt":"*title*: Benra 30mg *description*: Benralizumab administered subcutaneously every 4 weeks\n\n$$$\n\n","completion":" benralizumab %%%"}
{"prompt":"*title*: Benralizumab 100 mg *description*: Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" benralizumab %%%"}
{"prompt":"*title*: Benralizumab 200 mg *description*: Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" benralizumab %%%"}
{"prompt":"*title*: Benralizumab 25 mg *description*: Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" benralizumab %%%"}
{"prompt":"*title*: Botulinum Toxin 200 Units *description*: 200 units of Botox\u00ae\n\n$$$\n\n","completion":" botulinum toxins %%%"}
{"prompt":"*title*: Botulinum Toxin 300 Units *description*: 300 units of Botox\u00ae\n\n$$$\n\n","completion":" botulinum toxins %%%"}
{"prompt":"*title*: Budesonide *description*: Budesonide Turbuhaler 100 mcg (Pulmicort\u00ae Turbuhaler\u00ae), 100 - 400 mcg daily.\n\n$$$\n\n","completion":" budesonide %%%"}
{"prompt":"*title*: Buprenorphine Sublingual Spray 0.5 mg *description*: Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.\n\nBuprenorphine Sublingual Spray: Buprenorphine Sublingual Spray 0.5 mg\n\n$$$\n\n","completion":" buprenorphine %%%"}
{"prompt":"*title*: Carboplatin\/Paclitaxel\/Bevacizumab Then Bevacizumab *description*: Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg\/m2 and bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.\n\nPatients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.\n\nConsolidation (A): Patients received bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle for 1 year.\n\n$$$\n\n","completion":" bevacizumab ### carboplatin ### paclitaxel %%%"}
{"prompt":"*title*: Carboplatin\/Paclitaxel\/Bevacizumab Then Bevacizumab\/Erlotinib *description*: Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg\/m2 and bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.\n\nPatients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.\n\nConsolidation (AE): Patients received bevacizumab IV 15 mg\/kg on day 1 (+\/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year.\n\n$$$\n\n","completion":" carboplatin ### bevacizumab ### paclitaxel ### erlotinib %%%"}
{"prompt":"*title*: Carboxymethylcellulose 0.5%, Glycerin 0.9% *description*: carboxymethylcellulose 0.5%, glycerin 0.9%\n\n$$$\n\n","completion":" glycerin ### carboxymethylcellulose %%%"}
{"prompt":"*title*: Celecoxib *description*: Participants\n\n$$$\n\n","completion":" celecoxib %%%"}
{"prompt":"*title*: Celecoxib *description*: Patients receiving celebrex preoperative and postoperatively for 7 days\n\nCelecoxib\n\n$$$\n\n","completion":" celecoxib %%%"}
{"prompt":"*title*: Chemotherapy With Stem Cell Support *description*: This is a phase I\/II trial of sequential accelerated chemotherapy cycles with paclitaxel\/ifosfamide and paclitaxel\/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.\n\nfilgrastim\n\ncarboplatin\n\nifosfamide\n\npaclitaxel\n\nautologous hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\n$$$\n\n","completion":" paclitaxel ### carboplatin ### ifosfamide ### filgrastim ### autologous hematopoietic stem cell transplantation\n %%%"}
{"prompt":"*title*: Ciclesonide + Placebo *description*: Ciclesonide: Low dose inhaled corticosteroid (80 mcg\/puff two puffs twice daily)\n\n$$$\n\n","completion":" placebo ### ciclesonide %%%"}
{"prompt":"*title*: Ciclesonide + Vitamin D *description*: Vitamin D3: vitamin D (100,000 IU loading dose followed by 4,000 IU\/day)\n\nCiclesonide: Low dose inhaled corticosteroid (80 mcg\/puff two puffs twice daily)\n\n$$$\n\n","completion":" vitamin d ### ciclesonide %%%"}
{"prompt":"*title*: Clobazam High Dose *description*: 1.0 mg\/kg\/day; tablets; orally; for 15-18 weeks\n\n$$$\n\n","completion":" clobazam %%%"}
{"prompt":"*title*: Clobazam High Dose *description*: 5 to 40 mg\/day with doses in the morning and at bedtime; orally\n\n$$$\n\n","completion":" clobazam %%%"}
{"prompt":"*title*: Clobazam Low Dose *description*: 0.25 mg\/kg\/day; tablets; orally; for 15-18 weeks\n\n$$$\n\n","completion":" clobazam %%%"}
{"prompt":"*title*: Clobazam Low Dose *description*: 5 to 10 mg\/day with doses in the morning and at bedtime; orally\n\n$$$\n\n","completion":" clobazam %%%"}
{"prompt":"*title*: Clobazam Medium Dose *description*: 0.5 mg\/kg\/day; tablets; orally; for 15-18 weeks\n\n$$$\n\n","completion":" clobazam %%%"}
{"prompt":"*title*: Cohort 1 (Erlotinib Plus Romidepsin (8 mg\/m^2)) *description*: Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg\/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" erlotinib ### romidepsin %%%"}
{"prompt":"*title*: Cohort 2 (Erlotinib Plus Romidepsin (10 mg\/m^2)) *description*: Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg\/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" romidepsin ### erlotinib %%%"}
{"prompt":"*title*: Cohort 3 (Erlotinib Plus Romidepsin (10 mg\/m^2)) + Antiemetic Prophylaxis *description*: Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg\/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" erlotinib ### romidepsin ### antiemetic prophylaxis %%%"}
{"prompt":"*title*: Cohort 4 (Erlotinib Plus Romidepsin (8 mg\/m^2)) + Antiemetic Prophylaxis *description*: Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg\/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.\n\n$$$\n\n","completion":" romidepsin ### erlotinib ### antiemetic prophylaxis %%%"}
{"prompt":"*title*: Condensed RT Group *description*: Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.\n\ncondensed RT group: BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U\/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.\n\nTraining procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.\n\nDuring each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.\n\n$$$\n\n","completion":" bont-a %%%"}
{"prompt":"*title*: Deep NMB Using Rocuronium *description*: The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation\n\nDeep NMB using rocuronium: - Drug: rocuronium\n\nBolus dose: 0.7 mg\/kg\nContinuous infusion : 0.8-1.2 mg\/kg\/h for maintaining deep NMB (post tetanic count 1-2) during operation.\n\n$$$\n\n","completion":" rocuronium %%%"}
{"prompt":"*title*: Delayed Switch *description*: Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.\n\n$$$\n\n","completion":" rivastigmine %%%"}
{"prompt":"*title*: Dexedrine+tDCS+Speech Therapy *description*: 10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day\n\nDexedrine: 10 mg immediate release of Dexedrine\n\nActive tDCS: 1.5 mA tDCS anodal tDCS\n\nSpeech Therapy: 60 min of speech therapy\n\n$$$\n\n","completion":" tdcs ### dexedrine ### speech therapy %%%"}
{"prompt":"*title*: Dexedrine+tDCS+Speech Therapy *description*: The subjects received 10 mg D-AMP 30 minutes before the 60 minutes of SLT; first 20 min is simultaneous tDCS stimulation in this experiment\/arm.\n\n$$$\n\n","completion":" tdcs ### dexedrine ### speech therapy %%%"}
{"prompt":"*title*: Distributed RT Group *description*: Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.\n\ndistributed RT group: BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U\/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.\n\nTraining procedures There are total 24 training sessions following one week after injection. Participants in the distributed practice group will receive 2 sessions per week, for 12 weeks.\n\nDuring each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice.\n\n$$$\n\n","completion":" bont-a %%%"}
{"prompt":"*title*: Doubling Statin Dose *description*: simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.\n\n$$$\n\n","completion":" atorvastatin ### simvastatin %%%"}
{"prompt":"*title*: Dupilumab 300 mg q2w *description*: 2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20.\n\n$$$\n\n","completion":" dupilumab ### prednisone ### prednisolone ### q2w %%%"}
{"prompt":"*title*: Epidiolex *description*: The participants (or their caregivers) self-administered CBD 100mg\/mL oral solution at a starting dose of 5 mg\/kg\/day in twice daily dosing and titrated by 5 mg\/kg\/2 weeks up to 25 mg\/kg\/day. Additional increases in dosing, by 5 mg\/kg\/day up to a maximum of 50 mg\/kg\/day, was instituted at the discretion of the treating PI.\n\n$$$\n\n","completion":" cbd %%%"}
{"prompt":"*title*: Erlotinib and Bevacizumab *description*: Patients received erlotinib 150 mg daily with bevacizumab at 15mg\/kg until progression or prohibitive toxicity.\n\n$$$\n\n","completion":" erlotinib ### bevacizumab %%%"}
{"prompt":"*title*: Extended Release Lamotrigine *description*: Once daily dose of extended release lamotrigine given for two weeks following completion of part I of the study (regular lamotrigine)\n\n$$$\n\n","completion":" lamotrigine er %%%"}
{"prompt":"*title*: Ezetimibe\/Simvastatin *description*: Ezetimibe\/simvastatin 10\/20 mg tablets, taken once daily for six weeks\n\n$$$\n\n","completion":" ezetimibe ### simvastatin %%%"}
{"prompt":"*title*: GWP42003-P 25 mg\/kg\/Day *description*: Participants were randomized to receive GWP42003-P 25 milligrams per kilogram per day (mg\/kg\/day) (via oral twice daily [morning and evening] administration). Participants completed a 4-week dose escalation period, titrating up to their assigned dose, before continuing on a stable dose of blinded GWP42003-P for 12 weeks.\n\n$$$\n\n","completion":" gwp42003-p %%%"}
{"prompt":"*title*: GWP42003-P 50 mg\/kg\/Day *description*: Participants were randomized to receive GWP42003-P 50 mg\/kg\/day (via oral twice daily [morning and evening] administration). Participants completed a 4-week dose escalation period, titrating up to their assigned dose, before continuing on a stable dose of blinded GWP42003-P for 12 weeks.\n\n$$$\n\n","completion":" gwp42003-p %%%"}
{"prompt":"*title*: Haloperidol (Haldol) *description*: Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.\n\nHaloperidol: Patients receive 2.5 mg of IV haloperidol.\n\nNormal Saline: All patients receive a 1-liter bolus of normal saline (NS)\n\nDiphenhydramine: All patients receive 25 mg of intravenous (IV) diphenhydramine.\n\n$$$\n\n","completion":" haloperidol ### diphenhydramine %%%"}
{"prompt":"*title*: High Dose Cannabidiol Oral Solution [40 mg\/kg\/Day] *description*: High Dose [40 mg\/kg\/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg\/kg in the morning on Day 1 followed by total dose of 40 mg\/kg\/day (20 mg\/kg in the morning and 20 mg\/kg in the evening) on Days 4 to 10.\n\n$$$\n\n","completion":" cannabidiol %%%"}
{"prompt":"*title*: High Dose Edoxaban\/Placebo Warfarin *description*: Edoxaban tablets plus warfarin placebo tablets\n\n60mg Edoxaban tablets (high dose regimen): Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months\n\nplacebo warfarin: placebo warfarin\n\n$$$\n\n","completion":" edoxaban ### placebo %%%"}
{"prompt":"*title*: Immediate Release (IR) Lamotrigine *description*: Study population was on chronic IR lamotrigine therapy and first period of the study was a continuation of standard treatment with IR lamotrigine.\n\n$$$\n\n","completion":" lamotrigine ir %%%"}
{"prompt":"*title*: Immediate Switch *description*: Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.\n\n$$$\n\n","completion":" rivastigmine %%%"}
{"prompt":"*title*: Insulin Lispro + rHuPH20 *description*: Two, subcutaneous (SC) injections of 0.15 units per kilogram (U\/kg) insulin lispro with 3.75 nanograms per kilogram (ng\/kg) recombinant human hyaluronidase (rHuPH20), 9 to 42 days apart\n\n$$$\n\n","completion":" insulin lispro ### rhuph20 %%%"}
{"prompt":"*title*: Insulin Lispro Alone *description*: Two, subcutaneous (SC) injections of 0.15 units per kilogram (U\/kg) insulin lispro alone, 9 to 42 days apart\n\n$$$\n\n","completion":" insulin lispro %%%"}
{"prompt":"*title*: Intranasal Midazolam *description*: 0.2 mg\/kg Intranasal Midazolam for a seizure longer than 5 minutes\n\n$$$\n\n","completion":" midazolam %%%"}
{"prompt":"*title*: Intranasal Midazolam *description*: Median time to seizure cessation from medication administration to seizures stop time.\n\n$$$\n\n","completion":" midazolam %%%"}
{"prompt":"*title*: Intranasal Midazolam *description*: Patients who required oxygen at discharge from the Emergency Department\n\n$$$\n\n","completion":" midazolam %%%"}
{"prompt":"*title*: KPI-121 0.25% Ophthalmic Suspension *description*: Participants randomized to KPI-121 0.25% Ophthalmic Suspension\n\n$$$\n\n","completion":" kpi-121 %%%"}
{"prompt":"*title*: Ketamine *description*: Single bolus 0.5mg\/kg ketamine IV after induction of anesthesia\n\n$$$\n\n","completion":" ketamine %%%"}
{"prompt":"*title*: Ketorolac *description*: Participants\n\n$$$\n\n","completion":" ketorolac %%%"}
{"prompt":"*title*: Ketorolac *description*: Patients receiving scheduled ketorolac postoperatively\n\nKetorolac\n\n$$$\n\n","completion":" ketorolac %%%"}
{"prompt":"*title*: Letrozole *description*: 2.5 mg by mouth (PO) daily\n\n$$$\n\n","completion":" letrozole %%%"}
{"prompt":"*title*: Low Dose Cannabidiol Oral Solution [10 mg\/kg\/Day] *description*: Low Dose [10 milligrams\/kilogram\/day (mg\/kg\/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg\/kg in the morning on Day 1 followed by total dose of 10 mg\/kg\/day (5 mg\/kg in the morning and 5 mg\/kg in the evening) on Days 4 to 10.\n\n$$$\n\n","completion":" cannabidiol %%%"}
{"prompt":"*title*: Low Dose Edoxaban\/Placebo Warfarin *description*: Edoxaban tablets plus warfarin placebo tablets\n\n30mg Edoxaban tablets (low dose regimen): Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months\n\nplacebo warfarin: placebo warfarin\n\n$$$\n\n","completion":" placebo ### edoxaban %%%"}
{"prompt":"*title*: Lurasidone 160 mg *description*: Lurasidone 160 mg (4 tablets) taken orally once a day\n\n$$$\n\n","completion":" lurasidone %%%"}
{"prompt":"*title*: Lurasidone 80 mg *description*: Lurasidone 80 mg tablets taken orally once a day\n\n$$$\n\n","completion":" lurasidone %%%"}
{"prompt":"*title*: Metoclopramide (Reglan) *description*: Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.\n\nMetoclopramide: Patients receive 10 mg of intravenous (IV) metoclopramide.\n\nNormal Saline: All patients receive a 1-liter bolus of normal saline (NS)\n\nDiphenhydramine: All patients receive 25 mg of intravenous (IV) diphenhydramine.\n\n$$$\n\n","completion":" metoclopramide ### diphenhydramine %%%"}
{"prompt":"*title*: Metoclopramide Nasal Spray 10 mg *description*: metoclopramide: 30 minutes before meals and at bedtime for 4 weeks\n\n$$$\n\n","completion":" metoclopramide %%%"}
{"prompt":"*title*: Metoclopramide Nasal Spray 14 mg *description*: metoclopramide: 30 minutes before meals and at bedtime for 4 weeks\n\n$$$\n\n","completion":" metoclopramide %%%"}
{"prompt":"*title*: Mid Dose Cannabidiol Oral Solution [20 mg\/kg\/Day] *description*: Mid Dose [20 mg\/kg\/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg\/kg in the morning on Day 1 followed by total dose of 20 mg\/kg\/day (10 mg\/kg in the morning and 10 mg\/kg in the evening) on Days 4 to 10.\n\n$$$\n\n","completion":" cannabidiol %%%"}
{"prompt":"*title*: Moderate NMB Using Rocuronium *description*: The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation\n\nModerate NMB using rocuronium: - Drug: rocuronium\n\nBolus dose: none\nContinuous infusion: 0.2-0.6 mg\/kg\/h for maintaining moderate NMB (train of four 1-2) during operation.\n\n$$$\n\n","completion":" rocuronium %%%"}
{"prompt":"*title*: Montelukast 14 mg *description*: Montelukast 14 mg IV Administration\n\n$$$\n\n","completion":" montelukast %%%"}
{"prompt":"*title*: Montelukast 7 mg *description*: Montelukast 7 mg IV Administration\n\n$$$\n\n","completion":" montelukast %%%"}
{"prompt":"*title*: NTx\u00ae-265 High Dose *description*: hCG 385 \u00b5g (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" hcg ### epo %%%"}
{"prompt":"*title*: NTx\u00ae-265 Low Dose *description*: hCG 385 \u00b5g (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" hcg ### epo %%%"}
{"prompt":"*title*: NTx\u00ae-265 Medium Dose *description*: hCG 385 \u00b5g (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" epo ### hcg %%%"}
{"prompt":"*title*: Nasal Nicotine Spray *description*: 3 mg of nasal nicotine will be administered postoperatively.\n\n$$$\n\n","completion":" nicotine %%%"}
{"prompt":"*title*: Nasal Normal Saline Spray *description*: 1 ml of nasal normal saline spray will be administered postoperatively.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Nicotine Patch *description*: Transdermal nicotine patch\n\nTransdermal nicotine patch: 7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)\n\n$$$\n\n","completion":" nicotine %%%"}
{"prompt":"*title*: Non-Hodgkin's: ABT-888 & Cyclophosphamide *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" cyclophosphamide ### abt-888 %%%"}
{"prompt":"*title*: Non-Hodgkin's: Cyclophosphamide Alone *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days.\n\n$$$\n\n","completion":" cyclophosphamide %%%"}
{"prompt":"*title*: OAT + BMM + Beta-B *description*: Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)\n\n$$$\n\n","completion":" propranolol ### nadolol ### optimal acute therapy ### behavioral migraine management %%%"}
{"prompt":"*title*: OAT + BMM + PL *description*: Optimal Acute Therapy plus Behavioral Migraine Management plus placebo\n\n$$$\n\n","completion":" placebo ### optimal acute therapy ### behavioral migraine management %%%"}
{"prompt":"*title*: OAT + Beta Blocker (Beta-B) *description*: Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)\n\n$$$\n\n","completion":" nadolol ### propranolol ### optimal acute therapy %%%"}
{"prompt":"*title*: OAT + Placebo (PL) *description*: Optimal Acute Therapy plus Beta Blocker Placebo\n\n$$$\n\n","completion":" placebo ### optimal acute therapy %%%"}
{"prompt":"*title*: Open Trial Group *description*: The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.\n\nOlanzapine: 16-week open trial of olanzapine. The patients were started on a dose of 15 mg\/d by mouth, which could be adjusted to as low as 10 mg\/d or as high as 40 mg\/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.\n\n$$$\n\n","completion":" olanzapine %%%"}
{"prompt":"*title*: Open-label Extension Arm *description*: All participants started treatment with a daily rivastigmine 2.5 cm^2 patch. The dose was increased to 5, 7.5, and then 10 cm^2 after 4 weeks of treatment at each dose level. One patch was applied once daily. The dose level reached by each individual patient at the end of this 16 weeks was maintained for the rest of the study duration (Maintenance Period) for a total of 52 weeks. A predetermined \"allowed adjustment\" scheme was followed in participants who required dose adjustment due to low tolerability.\n\n$$$\n\n","completion":" rivastigmine %%%"}
{"prompt":"*title*: Paclitaxel, Ifosfamide, and Cisplatin *description*: -Paclitaxel is administered first, 120 mg\/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg\/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg\/m2 daily for five days every three weeks for four cycles.\n\npegfilgrastim\n\ncisplatin\n\nifosfamide\n\npaclitaxel\n\n$$$\n\n","completion":" paclitaxel ### ifosfamide ### cisplatin %%%"}
{"prompt":"*title*: Paliperidone *description*: Paliperidone Extended-Release (ER) oral tablet was administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.\n\n$$$\n\n","completion":" paliperidone er %%%"}
{"prompt":"*title*: Part B: E2006 10 mg *description*: Otherwise healthy participants with primary insomnia received E2006 10 mg, capsule, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" e2006 %%%"}
{"prompt":"*title*: Part B: E2006 2.5 mg *description*: Otherwise healthy participants with primary insomnia received E2006 2.5 mg, capsule, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" e2006 %%%"}
{"prompt":"*title*: Part B: E2006 25 mg *description*: Otherwise healthy participants with primary insomnia received E2006 25 mg (2 capsules of 10 mg each and 2 capsules of 2.5 mg each), orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" e2006 %%%"}
{"prompt":"*title*: Part B: E2006 Matched Placebo or Zolpidem Matched Placebo *description*: Otherwise healthy participants with primary insomnia received E2006-matched placebo capsules or zolpidem-matched placebo tablets, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Part B: Zolpidem 10 mg *description*: Otherwise healthy participants with primary insomnia received zolpidem 10 mg immediate release, tablet, orally in the evening, 30 minutes prior to habitual bed time (lights-out) on Day 1.\n\n$$$\n\n","completion":" zolpidem %%%"}
{"prompt":"*title*: Pembrolizumab + Epacadostat *description*: Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.\n\n$$$\n\n","completion":" epacadostat ### pembrolizumab %%%"}
{"prompt":"*title*: Pembrolizumab + Placebo *description*: Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.\n\n$$$\n\n","completion":" placebo ### pembrolizumab %%%"}
{"prompt":"*title*: Pen (Period 1) \/ Vial & Syringe (Period 2) *description*: Crossover study group of insulin glargine via SoloSTAR\u00ae pen in Period 1 and insulin glargine via vial and syringe in Period 2.\n\n$$$\n\n","completion":" insulin glargine %%%"}
{"prompt":"*title*: Pen (Period 1) \/ Vial & Syringe (Period 2) *description*: Crossover study group where participants were randomized to the sequence of insulin glargine via SoloSTAR\u00ae pen in Period 1 and insulin glargine via vial and syringe in Period 2.\n\n$$$\n\n","completion":" insulin glargine %%%"}
{"prompt":"*title*: Phase I Dose Finding *description*: Decitabine at escalating dose levels will be given IV for 1 hour x 5 days followed by Carboplatin given IV for 30 minutes on Day 8 at a dose corresponding to an AUC of 5.\n\n$$$\n\n","completion":" carboplatin ### decitabine %%%"}
{"prompt":"*title*: Placebo *description*: 0% OPC-12759 ophthalmic suspension received one drop of to both eyes four times a day for 4 weeks\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: 0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: 0.9 % saline bolus of equivalent volume\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Albiglutide matching placebo was administered once weekly as subcutaneous injection in the abdomen, thigh or upper arm region in addition to the standard of care therapy for diabetes and cardiovascular health.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Matching Placebo capsules orally: 1 dose the evening before surgery (approximately 12 hours prior to surgery), 1 dose approximately 2 hours before surgery followed by twice daily dosing for up to 6 post-operative weeks starting on POD 1.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Matching placebo\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Matching placebo to either lurasidone or quetiapine XR. The total for this group is 73 and the adverse events only add up to 69 because the total is based on all treatment emergent adverse events not limited to >= 5%.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Participants received placebo once daily (OD) in the evening from the dry powder inhaler (DPI) and placebo twice daily (BID) from the DISKUS\/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol\/salbutamol inhalation aerosol to be used as needed throughout the study.\n\n$$$\n\n","completion":" albuterol ### salbutamol ### placebo %%%"}
{"prompt":"*title*: Placebo *description*: Participants were randomized to receive placebo matched to GWP42003-P (via oral twice daily [morning and evening] administration) for 16 weeks.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Placebo to ZOMIG nasal spray\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: Saline\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo *description*: tablets; orally; daily for 15-18 weeks\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo + Carboplatin + Paclitaxel -> Placebo *description*: Participants received placebo to veliparib orally twice a day in combination with carboplatin given at an area under the curve [AUC] of 6 mg per milliliter per minute (mg\/mL\/min), every 3 weeks, and paclitaxel 175 mg per square meter (mg\/m\u00b2) of body-surface area (BSA), administered every 3 weeks, or 80 mg\/m\u00b2 administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.\n\n$$$\n\n","completion":" carboplatin ### paclitaxel ### placebo %%%"}
{"prompt":"*title*: Placebo Every 2 Weeks *description*: Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo Every 4 Weeks *description*: Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo Nasal Spray *description*: Placebo: 30 minutes before meals and at bedtime\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo Patch *description*: Placebo patch\n\nPlacebo patch: Placebo patch\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Placebo q2w *description*: 2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20.\n\n$$$\n\n","completion":" prednisolone ### prednisone %%%"}
{"prompt":"*title*: Placebo q2w *description*: 2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until week 20.\n\n$$$\n\n","completion":" placebo ### q2w %%%"}
{"prompt":"*title*: Placebo+tDCS+Speech Therapy *description*: 1.5 mA anodal tDCS, and speech therapy for 1 day\n\nActive tDCS: 1.5 mA tDCS anodal tDCS\n\nSpeech Therapy: 60 min of speech therapy\n\nPlacebo\n\n$$$\n\n","completion":" tdcs ### placebo ### speech therapy %%%"}
{"prompt":"*title*: Placebo+tDCS+Speech Therapy *description*: The subjects received placebo 30 minutes before the 60 minutes of SLT; first 20 min is simultaneous tDCS stimulation in this experiment\/arm.\n\n$$$\n\n","completion":" tdcs ### placebo ### speech therapy %%%"}
{"prompt":"*title*: Pregabalin *description*: Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later\n\n$$$\n\n","completion":" pregabalin %%%"}
{"prompt":"*title*: Pregabalin (150 mg) *description*: Pregabalin capsules orally 75 mg the evening before surgery (approximately 12 hours prior to surgery) followed by 75 mg approximately 2 hours before surgery followed by 150 mg\/day (75 mg twice daily) for up to 6 post-operative weeks starting on POD 1.\n\n$$$\n\n","completion":" pregabalin %%%"}
{"prompt":"*title*: Pregabalin (300 mg) *description*: Pregabalin capsules orally 150 mg the night before surgery (approximately 12 hours prior to surgery) followed by 150 mg approximately 2 hours before surgery followed by 300 mg\/day (150 mg twice daily) for up to 6 post-operative weeks starting on POD 1.\n\n$$$\n\n","completion":" pregabalin %%%"}
{"prompt":"*title*: QS-21 *description*: A cohort of participants who received IM injection of adjuvant QS-21 (50 micrograms) at Day 1, month 1, 3, 6 and 12\n\n$$$\n\n","completion":" qs-21 %%%"}
{"prompt":"*title*: Quetiapine XR 600mg *description*: Quetiapine XR 600 mg (4 tablets) orally taken once a day\n\n$$$\n\n","completion":" quetiapine xr %%%"}
{"prompt":"*title*: RESTASIS\u00ae *description*: 1 drop of RESTASIS\u00ae ophthalmic emulsion instilled in each eye twice a day for 6 months.\n\n$$$\n\n","completion":" restasis %%%"}
{"prompt":"*title*: Rectal Diazepam *description*: 0.3-0.5 Rectal Diazepam for a seizure lasting longer than 5 minutes\n\n$$$\n\n","completion":" diazepam %%%"}
{"prompt":"*title*: Rectal Diazepam *description*: Includes intubation\n\n$$$\n\n","completion":" diazepam %%%"}
{"prompt":"*title*: Rectal Diazepam *description*: Median time to seizure cessation from medication administration to seizures stop time.\n\n$$$\n\n","completion":" diazepam %%%"}
{"prompt":"*title*: Regular Human Insulin + rHuPH20 *description*: Two, subcutaneous (SC) injections of 0.15 units per kilogram (U\/kg) regular human insulin (RHI) with 3.75 nanograms per kilogram (ng\/kg) recombinant human hyaluronidase (rHuPH20), 9 to 42 days apart\n\n$$$\n\n","completion":" insulin ### rhuph20 %%%"}
{"prompt":"*title*: Rivastigmine 13.3 mg\/24 h Transdermal Patch *description*: Patients received rivastigmine 13.3 mg\/24 h (15 cm^2).\n\n$$$\n\n","completion":" rivastigmine %%%"}
{"prompt":"*title*: Rivastigmine 4.6 mg\/24 h Transdermal Patch *description*: Patients received rivastigmine 4.6 mg\/24 h (5 cm^2).\n\n$$$\n\n","completion":" rivastigmine %%%"}
{"prompt":"*title*: Rosuvastatin *description*: Rosuvastatin 10 mg tablets, taken once daily for six weeks.\n\n$$$\n\n","completion":" rosuvastatin %%%"}
{"prompt":"*title*: Saline Placebo *description*: saline SC, on Day 1, 3 and 5 of study participation, then saline IV, on Day 7, 8, and 9 of study participation\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Salmeterol 50 \u00b5g BID *description*: Participants received Salmeterol 50 \u00b5g BID from the DISKUS\/ACCUHALER (one inhalation in the morning and one inhalation in the evening) plus placebo OD in the evening from the DPI for 12 weeks. In addition, participants were provided supplemental albuterol\/salbutamol aerosol to be used as needed throughout the study.\n\n$$$\n\n","completion":" salmeterol ### albuterol ### salbutamol ### placebo %%%"}
{"prompt":"*title*: Single Arm, 50 mg\/kg of Levetiracetam *description*: Single arm, 50 mg\/kg of levetiracetam\n\n$$$\n\n","completion":" levetiracetam %%%"}
{"prompt":"*title*: Sodium Hyaluronate 0.18% *description*: sodium hyaluronate 0.18%\n\n$$$\n\n","completion":" sodium hyaluronate %%%"}
{"prompt":"*title*: Staccato Loxapine 0.625 mg *description*: inhalation of loxapine from a single 0.625 mg device\n\n$$$\n\n","completion":" loxapine %%%"}
{"prompt":"*title*: Staccato Loxapine 1.25 mg *description*: inhalation of loxapine from a two 0.625 mg devices\n\n$$$\n\n","completion":" loxapine %%%"}
{"prompt":"*title*: Staccato Loxapine 10 mg *description*: inhalation of loxapine from a two 5 mg devices\n\n$$$\n\n","completion":" loxapine %%%"}
{"prompt":"*title*: Staccato Loxapine 2.5 mg *description*: inhalation of loxapine from a single 2.5 mg device\n\n$$$\n\n","completion":" loxapine %%%"}
{"prompt":"*title*: Staccato Loxapine 5 mg *description*: inhalation of loxapine from a single 5 mg device\n\n$$$\n\n","completion":" loxapine %%%"}
{"prompt":"*title*: Standard of Care Narcotic Therapy *description*: Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.\n\nMorphine: Morphine\n\nOxycodone Hydrochloride: Oxycodone Hydrochloride 10 mg tablet\n\n$$$\n\n","completion":" morphine ### oxycodone %%%"}
{"prompt":"*title*: Sugar Pill *description*: 2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Sugar Pill *description*: A time by treatment group interaction showed decreased or no significant change in the gray matter volume estimated as number of voxels in a cluster with Valaclcovir compared to placebo\n\n$$$\n\n","completion":" placebo %%%"}
{"prompt":"*title*: Symbicort Turbuhaler *description*: 160\/4.5 \u00b5g delivered dose\n\n$$$\n\n","completion":" symbicort %%%"}
{"prompt":"*title*: Ticagrelor 60 mg *description*: Ticagrelor 60 mg twice daily (BD)\n\n$$$\n\n","completion":" ticagrelor %%%"}
{"prompt":"*title*: Ticagrelor 90 mg *description*: Ticagrelor 90 mg twice daily (BD)\n\n$$$\n\n","completion":" ticagrelor %%%"}
{"prompt":"*title*: Ticagrelor 90 mg Twice Per Day *description*: Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her\/his headache activity.\n\nTicagrelor 90 mg twice per day: Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.\n\n40 subjects were enrolled.\n\n$$$\n\n","completion":" ticagrelor %%%"}
{"prompt":"*title*: Treatment A *description*: Treatment A: 5 mg saxagliptin + 2 Glucophage XR 500 mg tablets, single dose under fed conditions\n\n$$$\n\n","completion":" saxagliptin ### glucophage xr %%%"}
{"prompt":"*title*: Treatment B *description*: Treatment B: Fixed dose combination (FDC) tablet (5 mg saxagliptin + 1000 mg metformin XR), single dose, under fed conditions\n\n$$$\n\n","completion":" saxagliptin ### metformin xr %%%"}
{"prompt":"*title*: Treatment C *description*: Ten(10) inhalations of Epinephrine CFC-MDI (220 mcg\/inhalation), totaling 2.20 mg of epinephrine, in 5 min\n\n$$$\n\n","completion":" epinephrine %%%"}
{"prompt":"*title*: Treatment T *description*: Ten (10) inhalations of E004 (125 mcg\/inhalation), totaling 1.25 mg of epinephrine, in 5 min\n\n$$$\n\n","completion":" epinephrine %%%"}
{"prompt":"*title*: Triple-negative Breast Cancer: Crossover *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.\n\n$$$\n\n","completion":" cyclophosphamide ### abt-888 %%%"}
{"prompt":"*title*: Triple-negative Breast Cancer: Cyclophosphamide & ABT-888 *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth on a continuous schedule.\n\n$$$\n\n","completion":" cyclophosphamide ### abt-888 %%%"}
{"prompt":"*title*: Triple-negative Breast Cancer: Cyclophosphamide Alone *description*: Oral cyclophosphamide 50mg by mouth (PO) for 21 days.\n\n$$$\n\n","completion":" cyclophosphamide %%%"}
{"prompt":"*title*: Usual Care *description*: Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.\n\n$$$\n\n","completion":" nan %%%"}
{"prompt":"*title*: Valacyclovir *description*: 1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks\n\n$$$\n\n","completion":" valacyclovir %%%"}
{"prompt":"*title*: Valacyclovir *description*: 1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.\n\n$$$\n\n","completion":" valacyclovir %%%"}
{"prompt":"*title*: Valacyclovir *description*: A time by treatment group interaction showed increased gray matter volume estimated as number of voxels in a cluster with Valaclcovir compared to placebo\n\n$$$\n\n","completion":" valacyclovir %%%"}
{"prompt":"*title*: Vehicle of KPI-121 0.25% Ophthalmic Suspension *description*: Participants randomized to Vehicle of KPI-121 0.25% Ophthalmic Suspension\n\n$$$\n\n","completion":" kpi-121 %%%"}
{"prompt":"*title*: Veliparib + Carboplatin + Paclitaxel -> Placebo *description*: Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg\/mL\/min every 3 weeks and paclitaxel 175 mg\/m\u00b2 of BSA administered every 3 weeks, or 80 mg\/m\u00b2 administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received matching placebo twice daily for an additional thirty 21-day cycles of maintenance therapy.\n\n$$$\n\n","completion":" veliparib ### carboplatin ### paclitaxel %%%"}
{"prompt":"*title*: Veliparib + Carboplatin + Paclitaxel -> Veliparib *description*: Participants received 150 mg veliparib orally twice a day in combination with carboplatin given at an AUC of 6 mg\/mL\/min every 3 weeks and paclitaxel 175 mg\/m\u00b2 of BSA administered every 3 weeks, or 80 mg\/m\u00b2 administered weekly, for six 21-day cycles.\n\nParticipants who completed chemotherapy without disease progression received single-agent veliparib at a dose of 300 mg twice daily for 2 weeks (transition period) and then 400 mg veliparib twice daily if the dose in the transition period was not associated with limiting side effects for an additional thirty 21-day cycles of maintenance therapy.\n\n$$$\n\n","completion":" carboplatin ### veliparib ### paclitaxel %%%"}
{"prompt":"*title*: Vial & Syringe (Period 1) \/ Pen (Period 2) *description*: Crossover study group where participants were randomized to the sequence of insulin glargine via vial and syringe in Period 1 and insulin glargine via SoloSTAR pen in Period 2.\n\n$$$\n\n","completion":" insulin glargine %%%"}
{"prompt":"*title*: Vilanteral 25 \u00b5g OD *description*: Participants received Vilanterol (VI) 25 micrograms (\u00b5g) OD in the evening from the DPI and placebo BID from the DISKUS\/ACCUHALER (one inhalation in the morning and one inhalation in the evening) for 12 weeks. In addition, participants were provided supplemental albuterol\/salbutamol aerosol to be used as needed throughout the study.\n\n$$$\n\n","completion":" vilanterol ### salbutamol ### albuterol ### placebo %%%"}
{"prompt":"*title*: Warfarin *description*: Subjects assigned to warfarin therapy.\n\nWarfarin: Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0\n\n$$$\n\n","completion":" warfarin %%%"}
{"prompt":"*title*: Warfarin\/Placebo Edoxaban *description*: Warfarin tablets plus placebo Edoxaban tablets\n\nwarfarin tablets: Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months\n\nplacebo edoxaban: placebo edoxaban\n\n$$$\n\n","completion":" placebo ### warfarin %%%"}
{"prompt":"*title*: ZOMIG 0.5 mg *description*: ZOMIG nasal spray\n\n$$$\n\n","completion":" zomig %%%"}
{"prompt":"*title*: ZOMIG 2.5 mg *description*: ZOMIG nasal spray\n\n$$$\n\n","completion":" zomig %%%"}
{"prompt":"*title*: ZOMIG 5 mg *description*: ZOMIG nasal spray\n\n$$$\n\n","completion":" zomig %%%"}
